In addition, these findings have important implications for the treatment of ovarian cancer patients, as they demonstrate the possibility of targeting the Hippo pathway in combination with the use of platinum-derived compounds in patients with low MYPT1 expression to reduce cancer recurrence and metastasis. The gene discussed is PPP1R12A; the disease is ovarian carcinoma.